The ADC wave shows no sign of breaking with the recent approval of ELAHERE for platinum resistant ovarian cancer, Pfizer’s jaw-dropping acquisition of Seagen for $43 billion, and BMS’ $1 billion+ pact ...
Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback